<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00736632</url>
  </required_header>
  <id_info>
    <org_study_id>201103002</org_study_id>
    <secondary_id>R01HL094818</secondary_id>
    <nct_id>NCT00736632</nct_id>
  </id_info>
  <brief_title>Vitamin D, Insulin Resistance, and Cardiovascular Disease</brief_title>
  <official_title>Vitamin D, Insulin Resistance, and Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent years, vitamin D has been shown not only to be important for bone and calcium
      metabolism but also for homeostasis of critical tissues involved in vascular disease in
      patients with diabetes. Epidemiological studies indicated the high prevalence of vitamin D
      deficiency among Type 2 DM patients and suggest an increased risk of cardiovascular disease
      and hypertension with low vitamin D levels. The objective of this proposal is to evaluate the
      effects of vitamin D replacement on blood pressure control and vascular disease in vitamin D
      deficient hypertensive patients with diabetes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blinded, placebo controlled trial. Patients who meet the inclusion criteria
      will be randomized to placebo or 25(OH)D3, 4,000 IU/d orally for 16 weeks. Enrolled patients
      will be tested for 24h-blood pressure, brachial arterial blood flow, vascular inflammatory
      markers and macrophage inflammatory response to modified-lipoproteins at baseline, middle and
      at the end of the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypertension</measure>
    <time_frame>0, 2, and 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brachial artery response to hyperemia</measure>
    <time_frame>0, 2, and 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic inflammatory markers and macrophage inflammatory response to modified-lipoproteins</measure>
    <time_frame>0 and 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and urinary calcium measurements</measure>
    <time_frame>Monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Insulin Resistance</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the control group will receive placebo pills (instead of vitamin D) and calcium carbonate 500 mg twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the vitamin D group will receive cholecalciferol 4000 units daily and calcium carbonate 500 mg twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Cholecalciferol 4000 units orally daily Calcium carbonate 500 mg orally twice daily</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>Vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill orally daily Calcium carbonate 500 mg twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  25 (OH) vitamin D levels &lt; 25 ng/ml

          -  Age 25 to 80 years

          -  Not on insulin for diabetes treatment

          -  HbA1c 5.5% -9.5%

          -  Mild/moderately increased blood pressure (systolic 120-160, diastolic 80-100) off BP
             medications

        Exclusion Criteria:

          -  Pregnancy

          -  Patients with systolic &gt;160 or diastolic &gt;100 mmHg

          -  High urine calcium or history of recurrent kidney stones

          -  Cardiovascular disease

          -  Stage 3 or worse chronic kidney disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Bernal-MIzrachi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Universiy</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://endo.wustl.edu</url>
    <description>Washington University Endocrinology Department website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2008</study_first_submitted>
  <study_first_submitted_qc>August 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2008</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

